StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold

Seres Therapeutics (NASDAQ:MCRB) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

MCRB has been the topic of a number of other research reports. The Goldman Sachs Group decreased their price target on shares of Seres Therapeutics from $20.00 to $15.00 and set a “sell” rating on the stock in a research note on Friday, March 14th. Chardan Capital reissued a “neutral” rating and issued a $6.00 price target (up previously from $1.25) on shares of Seres Therapeutics in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Seres Therapeutics has an average rating of “Hold” and an average target price of $73.67.

Seres Therapeutics Stock Performance

NASDAQ:MCRB opened at $7.05 on Friday. The firm’s 50-day moving average is $11.67 and its 200-day moving average is $14.66. The company has a market cap of $61.46 million, a price-to-earnings ratio of -30.65 and a beta of 2.89. Seres Therapeutics has a 52-week low of $6.64 and a 52-week high of $30.60.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($1.57). Equities analysts predict that Seres Therapeutics will post -0.38 EPS for the current year.

Institutional Trading of Seres Therapeutics

Several large investors have recently added to or reduced their stakes in MCRB. Avantax Advisory Services Inc. grew its position in Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 28,500 shares during the last quarter. SBI Securities Co. Ltd. boosted its stake in Seres Therapeutics by 221.8% in the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 48,013 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 37,866 shares during the last quarter. Virtu Financial LLC increased its stake in shares of Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 18,191 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 44,461 shares during the last quarter. 59.34% of the stock is owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.